Alvotech initiates confirmatory patient study for avt03, a proposed biosimilar for prolia® and xgeva®

Reykjavik, iceland, aug. 25, 2022 (globe newswire) -- alvotech (nasdaq: alvo), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a confirmatory patient study for avt03 (denosumab), a biosimilar candidate to prolia® and xgeva®. the objective of the study is to demonstrate clinical similarity of avt03 to prolia® in terms of efficacy, safety, immunogenicity, and pharmacokinetics in postmenopausal women with osteoporosis. the results from this trial will be used to support additional indications for avt03 to xgeva® based on extrapolation.
ALVO Ratings Summary
ALVO Quant Ranking